HOME >> BIOLOGY >> NEWS
Vanderbilt's John Oates wins clinical research award

John A. Oates Jr., M.D., Thomas F. Frist Sr. Professor of Medicine and professor of Pharmacology at Vanderbilt University Medical Center, received the Sixteenth Annual Award of Excellence in Clinical Research from the General Clinical Research Centers Program April 17.

The award acknowledges outstanding clinical research, supported by the National Center for Research Resources of the National Institutes of Health.

The $5,000 award and certificate was conferred during the General Clinical Research Centers Program Directors meeting in Chicago. At the meeting, Oates delivered a lecture titled "Investigation on the Contribution of Cyclooxygenases to Human Disease."

"Dr. Oates is a legend in Clinical Research. He put Vanderbilt's clinical research on the map, and I was personally excited to propose him for this award, and gratified that others recognized, as we do, his enormous contributions," said Alastair Wood, M.D., associate dean of external affairs at Vanderbilt.

"There are several important features or characteristics of Vanderbilt that nurtured the research that went on here -- the intent of Vanderbilt Pharmacology to include human pharmacology within the scope of the academic mission of the department," Oates said. "Their commitment to it has brought strong basic science to bear on our clinical research. For the investigation of human pharmacology, this has been an ideal setting."

Oates said the Vanderbilt General Clinical Research Center has been recognized as one of the leading GCRC's in the United States, and a great asset to the Medical School.

"The General Clinical Research Center has provided essential resources for our research, initially under the leadership of Elliot Newman, and more recently, David Robertson," Oates said.

"Recently NIH leadership has rediscovered the importance of patient-oriented research and has taken a number of helpful steps to support it," Robertson said. "As attention has focused on the na
'"/>

Contact: Clinton Colmenares
clinton.colmenares@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
19-Apr-2004


Page: 1 2

Related biology news :

1. Researchers at Vanderbilts Free-Electron Laser Center are developing new forms of laser surgery, improved X-ray technology, and better methods for protein identification
2. Matrisian named Vanderbilts first chair of cancer biology
3. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
4. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
5. Innovative ceramic-on-metal hip replacements to undergo clinical trials
6. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
7. Warren Pharmaceuticals publishes results of preclinical evaluation
8. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
9. Scientists characterize new breast tumor subtypes with poor clinical outcomes
10. Uncertainty in clinical tests raises health care costs
11. Germany starts clinical development of a new tuberculosis vaccine

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vanderbilt John Oates wins clinical research award

(Date:5/22/2013)... novel technique that can detect molecular variants in chemical ... of the most important, though time-consuming, processes in analytical ... Nature , post-doctoral researcher David Patterson, Professor of ... Center for Free-Electron Laser Science (CFEL) in Hamburg, Germany ... to identify molecular variants apart, and to determine how ...
(Date:5/22/2013)... environmental and human health effects from disposal of ... led scientists to recommend stronger government policies to ... battery materials. That,s the conclusion of a new ... & Technology . , Oladele A. Ogunseitan and ... mainstays for powering everything from smart phones to ...
(Date:5/22/2013)... Calif., May 22, 2013 Early screening for prostate ... pregnancy testing is for women, thanks to UC Irvine ... American Chemical Society . , After more than a ... way to clearly identify clinically usable markers for prostate ... detected far sooner, with greater accuracy and at dramatically ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
(Date:5/24/2013)... The Oklahoma tornado left the ... the mayor of Moore, one of the heavily damaged towns, ... report from cnn.com. Reaching out to also be of help, ... Safe Shield to counter the looming mold problem. , The ... 22, 2013, caused 24 deaths, My Cleaning Products shared. Ten ...
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
(Date:5/23/2013)... Wis. , May 23, 2013 ... researcher, developer, and marketer of over-the-counter (OTC) medicinal ... its research opinion on the company based on ... , Non-Prescription, All Natural Product to ... the Product Outperforms #1 Prescription Competitor , ...
(Date:5/23/2013)... May 23, 2013  Saddleback Memorial Medical Center in ... the first hospital on the West Coast to perform ... surgical option provides women with a state-of-the-art, minimally invasive ... Marc Winter , M.D., a highly regarded ... medical director of minimally invasive surgery at Saddleback Memorial, ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3
Cached News: